Name: Alvaro Rascon Role(s)

Name: Diana Terreros Role(s)

Name: John Sherman Role(s)

Name: Timothy Millea Role(s)

Name: Jesse Morrissey Role(s)

LAB 2 WRITEUP
Descriptive Statistics
Experiment 1
Dosage (0mg): Mean (3.834); Standard Deviation (1.523010177); Standard Error (0.481618106)
Dosage (5mg): Mean (8.932); Standard Deviation (1.593931547); Standard Error (0.504045412)
Dosage (10mg): Mean (61.622); Standard Deviation (30.11069386); Standard Error (9.521837451)
Dosage (15mg): Mean (657.941); Standard Deviation (212.9429762); Standard Error (67.33848166)
Experiment 2
Dosage (0mg): Mean (11.112); Standard Deviation (2.225551617); Standard Error (0.995296941)
Dosage (10mg): Mean (10.516); Standard Deviation (7.402885924); Standard Error (3.310671231)
Results
Experiment 1
_{}
Experiment 2
(Please include welllabeled graphs of the results.)
Analysis
Experiment 1
Tests of the effects of varying LPS doses on rats showed that the drug did not sharply influence Inflammotin levels. At a pvalue of 0.86, the data shows that the change in Inflammotin levels were not statistically significant, meaning we cannot prove the slight changes in Inflammotin can be attributed to the LPS dose.
Experiment 2
Tests of the effects of varying LPS doses on humans showed sharp increases in Inflammotin levels at increasing LPS doses. Producing a pvalue of 1.1E16, the data has proven that the effect of LPS on Inflammotin in humans is statistically significant for the experiment. The Bonferroni TTests produced values below the desired value of 0.008333.
(Using inferential statistics, please determine statistically significant differences in the data.)
Summary/Discussion
In Experiment 1, data concerning the effects of ranging LPS doses on inflammotin levels in rats showed that the drug did not affect inflammotin levels in rats enough to be significant. The average inflammotin levels were increased slightly at the 10mg LPS dose, but with a pvalue of 0.86 the effect is not significant enough to prove that the drug was responsible for the very slight increases. In Experiment 2, human subjects with ages ranging from 6082 showed sharp increases in their Inflammotin levels with increasing LPS doses. With Inflammotin averages increasing tenfold between 10mg and 15mg doses (pvalue=6.4824E08 between 10mg and 15mg), the effect of LPS on Inflammotin levels in humans seems to be statistically significant.
(Please discuss the results and statistical analysis from both experiments. State your conclusion.)
